Crystal structure of (S)-2-[(3S,8S,9S,10R,13S,14S,-17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta-[a]phenanthren-17-yl]-N-methoxy-N-methylpropanamide (Fernholz Weinreb amide)

Peer reviewedPublisher PD

Indenoindoles and cyclopentacarbazoles as bioactive compounds: Synthesis and biological applications

International audienceIndenoindoles and their isomers cyclopentacarbazoles represent a wide class of synthetic and natural compounds. The great interest of these structures in (bio)organic chemistry is due to the use of various building blocks to get the elemental four ring structure. Depending on the synthetic route chosen, the chemists can achieve a large number of regioisomers. Each regioisomer can be considered as a template for specific functionalizations. Therefore, this mini-review aims (i) to present an overview on how to access this large family of heterocyclic compounds and (ii) to discuss their various biological applications and drug development in oncology (e.g. kinases), in CNS disorders (e.g. Alzheimer's disease), in endocrinology (e.g. hormone replacement therapy) and oxidative stress (e.g. organ preservation). Past and present works will be presented through the systems 6-5-5-6 and 6-5-6-5 (combination of 6-membered and 5-membered rings)

Carbazole scaffolds in cancer therapy: a review from 2012 to 2018

International audienceFor over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic-carbazole motif to fused tetra-, penta-, hexa-and heptacyclic carba-zoles. To date, three derivatives are available on the market and approved in cancer therapy

Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles

International audienc

Synthesis and biological evaluation of zinc chelating compounds as metallo-β-lactamase inhibitors

International audienceThe syntheses of metallo-β-lactamase inhibitors comprising chelating moieties, with varying zinc affinities,and peptides partly inspired from bacterial peptide sequences, have been undertaken. The zinc chelatorstrength was varied using the following chelators, arranged in order of ascending binding affinity:dipicolylamine (DPA, tridentate), dipicolyl-1,2,3-triazolylmethylamine (DPTA, tetradentate) dipicolyl ethylenediamine(DPED, tetradentate) and trispicolyl ethylenediamine (TPED, pentadentate). The chosen peptideswere mainly based on the known sequence of the C-terminus of the bacterial peptidoglycan precursors.Biological evaluation on clinical bacterial isolates, harbouring either the NDM-1 or VIM-2 metallo-β-lactamase, showed a clear relationship between the zinc chelator strength and restoration of meropenemactivity. However, evaluation of toxicity on different cancer cell lines demonstrated a similar trend, and thusinclusion of the bacterial peptides did possess rather high toxicity towards eukaryotic cells

Synthesis and preclinical evaluation of TPA-based zinc chelators as metallo-β-lactamase inhibitors

International audienc

ALICE addentum to the Technical Design Report of the time of flight system (TOF)

ALIC